Compare KLTR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | AGEN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 178.2M |
| IPO Year | 2021 | 1999 |
| Metric | KLTR | AGEN |
|---|---|---|
| Price | $1.28 | $3.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $14.50 |
| AVG Volume (30 Days) | 403.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,854,000.00 | $42,877,086.00 |
| Revenue This Year | $2.96 | $107.63 |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | 1.20 | ★ 89.95 |
| 52 Week Low | $1.06 | $2.63 |
| 52 Week High | $2.29 | $7.34 |
| Indicator | KLTR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 49.56 |
| Support Level | $1.21 | $2.96 |
| Resistance Level | $1.68 | $4.58 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 77.19 | 37.53 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.